Dr Richard Fuller BMedSci (Hons) BMBS MRCGP LFHom
Working full-time with Dr Julian Kenyon, founder of the British Society of Integrated Medicine and British Medical Acupuncture Society. Dr Fuller provides integrated treatment programmes tailored to the needs of the individual, encompassing immune support, nutritional medicine and specific techniques such as Sonodynamic Photodynamic Therapy, Dendritic Cell Vaccination and psychological support using approaches such as Mindfulness Based Cognitive Therapy. Over the last 12 months Dr Fuller has established the first service providing Enhanced External Counterpulsation (EECP) for angina and heart disease in the South of England. This is a non-invasive technique, and is a management option for ongoing angina symptoms, including post-CABG or where surgery is not feasible or too high risk. He has written an informational website www.eecp.co.uk, arranged a conference for local Cardiologists and successfully achieved NHS funding via the South Central Cardiac Network for an EECP treatment Pilot Scheme.
2009 - Activated Cancer Therapy Using Light and Ultrasound - A Case Series of
Sonodynamic Photodynamic Therapy in 115 Patients over a 4 Year Period
Activated Cancer Therapy (ACT), also known as Sonodynamic Photodynamic Therapy (SPDT) is a novel therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound-activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the efficacy of photodynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents a promising development to activated sensitiser therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment of deeper tumour sites than is currently achievable with photodynamic therapy. This case series of 115 patients with a variety of cancer diagnoses reports on experiences of this treatment over a 4 year period using sublingual administration of a new dual activation agent, Sonnelux-1, followed by a protocol of LED light and low-intensity ultrasound exposure. Initial clinical observation suggests SPDT is worthy of further investigation as an effective and well tolerated treatment for a wide variety of primary and metastatic tumours, including those refractory to chemotherapy.